European evidence based consensus on the diagnosis and management of Crohn's disease: Special situations

Gut

Volumn 55, Issue SUPPL. 1, 2006, Pages

  Caprilli, R ^c   Gassull, M A ^d   Escher, J C ^e   Moser, G ^f   Munkholm, P ^g   Forbes, A ^h   Hommes, D W ⁱ   Lochs, H ^j   Angelucci, E ^k   Cocco, A ^c   Vucelic, B ^l   Hildebrand, H ^m   Kolacek, S ⁿ   Riis, L ^g   Lukas, M ^o   De Franchis, R ^p   Hamilton, M ^q   Jantschek, G ^r   Michetti, P ^s   O'Morain, C ^t   Anwar, M M ^t   Freitas, J L ^u   Mouzas, I A ^v   Baert, F ^w   Mitchell, R ^x   Hawkey, C J ^y   Travis, S P L ^a   Stange, E F ^b   more..

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^f UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

ⁱ ACADEMIC MEDICAL CENTER   (Netherlands)

^j HUMBOLDT UNIVERSITY   (Germany)

^k POLICLINICO UMBERTO I   (Italy)

^l KBC Zagreb   (Croatia)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁿ Croatia   (Croatia)

^o CHARLES UNIVERSITY   (Czech Republic)

^p Istituto di Medicina Interna   (Italy)

^q ROYAL FREE HOSPITAL   (United Kingdom)

^r Royal Free Hospital ^*  (Germany)

^s LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^t ADELAIDE AND MEATH HOSPITAL   (Ireland)

^u HOSPITAL GARCIA DE ORTA   (Portugal)

^v UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^w Heilig Hart Ziekenhuis   (Belgium)

^x EFFCA   (United Kingdom)

^y NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; ENEMA; FISH OIL; GRANULOCYTE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 10; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METOCLOPRAMIDE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORNIDAZOLE; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; PYRIDOXINE; QUINOLONE DERIVATIVE; SALAZOSULFAPYRIDINE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; THALIDOMIDE; TSUKUBAENOLIDE; UNINDEXED DRUG;

ABSCESS DRAINAGE; ABSENCE OF SIDE EFFECTS; ALTERNATIVE MEDICINE; ARTHRITIS; ARTHROPATHY; BONE DEVELOPMENT; CARCINOGENICITY; CHROMOSOME DAMAGE; CLEFT PALATE; CLINICAL TRIAL; CROHN DISEASE; DELIVERY; DIET THERAPY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISTRESS SYNDROME; DOCTOR PATIENT RELATION; DRUG EFFECT; DRUG SAFETY; ELECTIVE SURGERY; ERYTHEMA NODOSUM; EUROPE; EVIDENCE BASED PRACTICE; EYE DISEASE; FERTILITY; FETUS DISEASE; FISTULA; GROWTH RETARDATION; HEMANGIOMA; HEPATOBILIARY DISEASE; HUMAN; HYPERBARIC OXYGEN; LOW BIRTH WEIGHT; META ANALYSIS; METABOLIC BONE DISEASE; MORTALITY; MUTAGENIC ACTIVITY; NEURAL TUBE DEFECT; NONHUMAN; PATIENT CARE; PHYSIOTHERAPY; POSTOPERATIVE PERIOD; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOSOCIAL CARE; PSYCHOSOMATICS; PSYCHOTHERAPY; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; RISK FACTOR; SOCIAL PSYCHOLOGY; SPONTANEOUS ABORTION; SUPPOSITORY; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; BONE DISEASES, METABOLIC; COMPLEMENTARY THERAPIES; CROHN DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; INTESTINAL FISTULA; MESALAMINE; PHYSICIAN-PATIENT RELATIONS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PSYCHOTHERAPY; QUALITY OF LIFE; RECURRENCE; RISK FACTORS; SKIN DISEASES;

EID: 33144463875     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.081950c     Document Type: Review

References (340)

1. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63.
2. Caprilli R, Andreoli A, Capurso L, Gruppo Italiano per lo Studio del Colon e del Retto (GISC), et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of CD. Aliment Pharmacol Ther 1994;8:35-43.
3. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665-72.
4. Whelan G, Farmer RG, Fazio VW, Goormastic M. Recurrence after surgery in Crohn's disease. Gastroenterology 1985;88:1826-33.
5. Tytgat GNJ, Mulder CJJ, Brummelkamp WH. Endoscopic lesions in Crohn's disease early after ileocecal resection. Endoscopy 1988;20:260-2.
6. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualized ileal ulcers preceding the symptoms. Gut 1992;33:331-5.
7. Michelassi F, Balestracci T, Chappell R, et al. Primary and recurrent Crohn's disease. Experience with 1379 patients. Ann Surg 1991;214:230-40.
8. Williams JG, Wong WD, Rothenberger DA, et al. Recurrence of Crohn's disease after resection. Br J Surg 1991;78:10-19.
9. Goldberg PA, Wright JP, Gerber M, et al. Incidence of surgical resection for Crohn's disease. Dis Colon Rectum 1993;36:736-9.
10. Borley NR, Mortensen NJ, Jewell DP. Preventing postoperative recurrence of Crohn's disease. Br J Surg 1997;84:1493-502.
11. Viscido A, Corrao G, Taddei G, et al. "Crohn's disease activity index" is inaccurate to detect the post-operative recurrence in Crohn's disease. A GISC study. Ital J Gastroenterol Hepatol 1999;31:274-9.
12. Cammà C, Giunta M, Rosselli M, et al. 5-aminosalicylic acid in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73.
13. Cottone M, Rosselli M, Orlando A, et al. Smoking habitus and recurrence in Crohn's disease. Gastroenterology 1994;106:643-8.
14. Breuer-Katschusky BD, Hollander N, et al. Effect of cigarette smoking on the course of Crohn's disease. Eur J Gastroenterol Hepatol 1996;8:225-8.
15. Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990;98:1123-8.
16. Moskovitz D, McLeod RS, Greenberg GR, et al. Operative and environmental risk factors for recurrent Crohn's disease. Int J Colorectal Dis 1999;14:224-6.
17. D'Haens G, Gasparaitis AE, Hanauer SB. Duration of recurrent ileitis after ileocolonic resection correlates with preseurgical extent of Crohn's disease. Gut 1995;36:715-17.
18. McLeod R, Wolff B, Steinhart HA. Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease. Gastroenterology 1997;113:1823-7.
19. Kotanagi H, Kramer K, Fazio V, et al. Do microscopic abnormalities at resection margins correlate with increased anastomotic recurrence in Crohn's disease? Dis Colon Rectum 1991;34:909-16.
20. Aeberhand P, Berchtold W, Riedtmann HJ, et al. Surgical recurrence of perforating and non-perforating Crohn's disease. A study of 101 surgically treated patients. Dis Colon Rectum 1996;39:80-7.
21. Lock MR, Farmer RG, Fazio VW, et al. Recurrence and reoperation for Crohn's disease: the role of disease location in prognosis. N Engl J Med 1981;304:1586-8.
22. Hellborg R, Hulten L, Rosengren C, et al. The recurrence rate after primary excisional surgery for Crohn's disease. Acta Chir Scand 1980;146:435-43.
23. Lindhagen T, Ekelund G, Leandoer L, et al. Recurrence rate after surgical treatment of Crohn's disease. Scand J Gastroenterol 1983;18:1037-44.
24. Trnka YM, Glotzer DJ, Kasdon EJ, et al. The long-term outcome of restorative operation in Crohn's disease. Influence of location, prognostic factors and surgical guidelines. Ann Surg 1982;196:345-55.
25. Shivananda S, Hordijk ML, Pena SA, et al. Crohn's disease: risk of recurrence and reoperation in a defined population. Gut 1989;30:990-8.
26. Ellis L, Calhoun P, Kaiser DL, et al. Post-operative recurrence in Crohn's disease. The effect of the initial length of bowel resection and operative procedure. Ann Surg 1984;199:340-7.
27. Bergman L, Krause U. Crohn's disease: a long-term study of the clinical course in 186 patients. Scand J Gastroenterol 1977;12:937-44.
28. Nygaard K, Fausa O. Crohn's disease. Recurrence after surgical treatment. Scand J Gastroenterol 1977;12:577-84.
29. Karesen R, Serch-Hanssen A, Thoresen BO, et al. Crohn's disease: long-term results of surgical treatment. Scand J Gastroenterol 1981;16:57-64.
30. Himal HS, Belliveau PB. Prognosis after surgical treatment for granulomatous enteritis and colitis. Am J Surg 1981;142:347-9.
31. Mekhjiam HS, Switz DM, Watts HD, et al. National cooperative Crohn's disease study: factors determining recurrence of Crohn's disease after surgery. Gastroenterology 1979;77:907-13.
32. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and post-operative recurrence in Crohn's disease. Ann Surg 2000;210:38-45.
33. Atwell JD, Duthie HL, Goligher JC. The outcome of Crohn's disease. Br J Surg 1965;52:966-72.
34. Softley A, Myren J, Clamp SE, et al. Factors affecting recurrence after surgery for Crohn's disease. Scand J Gastroenterol Suppl 1988;144:S31-4.
35. Higgens CS, Allan RN. Crohn's disease of the distal ileum. Gut 1980;21:933-40.
36. Truelove SC, Pena AS. Course and prognosis of Crohn's disease. Gut 1976;17:192-201.
37. De Dombal FT, Burton I, Goligher JC. Recurrence of Crohn's disease after primary excisional surgery. Gut 1971;12:519-27.
38. Stahlgren LH, Ferguson LK. The results of surgical treatment of chronic regional enteritis. JAMA 1961;175:986-9.
39. Sachar DB, Wolfson DM, Greenstein AJ, et al. Risk factors for post-operative recurrence of Crohn's disease. Gastroenterology 1983;85:917-21.
40. Wolfson DM, Sachar DB, Cohen A, et al. Granulomas do not affect post-operative recurrence in Crohn's disease. Gastroenterology 1982;83:405-9.
41. Fawaz KA, Glotzer DJ, Goldman H, et al. Ulcerative colitis and Crohn's disease of the colon - a comparison of the long-term post-operative course. Gastroenterology 1976;71:372-8.
42. Homan WP, Gray GF, Dineen P. Granulomes in Crohn's disease. Lancet 1978;ii:112.
43. Speranza V, Simi M, Leardi S, et al. Recurrence of Crohn's disease after resection. Are there any risk factors? J Clin Gastroenterol 1986;8:640-6.
44. Van Pattern EN, Bargen JA, Dockerty MB, et al. Regional enteritis. Gastroenterology 1954;26:347-450.
45. Cooke WT, Mallas E, Prior P, et al. Crohn's disease: course, treatment and long-term prognosis. Q J Med 1980;49:363-84.
46. Kyle J. Prognosis after ileal resection for Crohn's disease. Br J Surg 1971;58:735-7.
47. Lautenbach E, Berlin JA, Lichtenstein GR. Risk factors for early post-operative recurrence of Crohn's disease. Gastroenterology 1998;115:259-67.
48. Greenstein AJ, Lachman P, Sachar DB, et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 1988;29:588-92.
49. Sachar DB, Subrami K, Mauer K, et al. Patterns of post-operative recurrence in fistulizing and stenotic Crohn's disease. A retrospective cohort study of 71 patients. J Clin Gastroenterol 1996;22:114-16.
50. McDonald PJ, Fazio VW, Farmer RG, et al. Perforation and non-perforating Crohn's disease. An unpredictable guide to recurrence after surgery. Dis Colon Rectum 1989;32:117-20.
51. Caprilli R, Corrao G, Taddei G, et al. Prognostic factors for post-operative recurrence of Crohn's disease. Dis Colon Rectum 1996;39:1-7.
52. Griffiths AM, Wesson DE, Shadling B, et al. Factors influencing post-operative recurrence of Crohn's disease in childhood. Gut 1991;32:491-5.
53. Caprilli R, Taddei G, Viscido A. In favour of prophylactic treatment for post-operative recurrence in Crohn's disease. Ital J Gastroenterol Hepatol 1998;30:219-25.
54. Breslin NP, Sutherland LR. The case against routine post-operative therapy for prevention of recurrence in Crohn's disease. Ital J Gastroenterol Hepatol 1998;30:226-30.
55. McLeod RS, Wolff BG, Steinhart AH, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995;109:404-13.
56. Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology 1995;108:345-9.
57. Lochs H, Mayer M, Fleig WE, ECCDS, et al. Prophylaxis of post-operative relapse in Crohn's disease with mesalamine: European cooperative Crohn's disease study VI. Gastroenterology 2000;118:264-73.
58. Cottone M, Cammà C. Mesalamine and relapse prevention in Crohn's disease. Gastroenterology 2000;118:597.
59. Caprilli R, Cottone M, Tonelli F, et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Aliment Pharmacol Ther 2003;17:517-23.
60. Cammà C, Viscido A, Latella G, et al. Mesalamine in the prevention of clinical and endoscopic post-operative recurrence of Crohn's disease: a meta-analysis. Dig Liver Dis 2002;34:A86).
61. Florent C, Cortot A, Quandale P, et al. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Eur J Gastroenterol Hepatol 1996;8:229-33.
62. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
63. Rutgeerts P, Assche GV, Vermeire S, et al. Ornidazole for prophylaxis of post-operative Crohn's disease: a randomized, double blind, placebo-controlled trial. Gastroenterology 2005;128:856-61.
64. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Post-operative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine or placebo: a 2 year trial. Gastroenterology 2004;127:723-9.
65. Korelitz B, Hanauer S, Rutgeerts P, et al. Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: a 2 year multicenter trial. Gastroenterology 1998;114:A1011.
66. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-9.
67. Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence in Crohn's disease: a randomized controlled study vs mesalamine. Gastroenterology 2000;118:A781.
68. Colombel JF, Rutgeerts P, Malchow H, et al. Interleukin 10 (Tenovil) in the prevention of post-operative recurrence of Crohn's disease. Gut 2001;49:42-6.
69. Viscido A, Corrao G, Taddei G, et al. Crohn's disease activity index is inaccurate to detect the post-operative recurrence in Crohn's disease. A GISC study. Ital J Gastroenterol Hepatol 1999;31:274-9.
70. Maccioni F, Viscido A, Marini M, et al. MRI evaluation of Crohn's disease of the small and large bowel with the use of negative superparamagnetic oral contrast agents. Abdom Imaging 2002;27:384-93.
71. Parente F, Greco S, Molteni M, et al. Modern imaging of Crohn's disease using bowel ultrasound. Inflamm Bowel Dis 2004;10:452-61.
72. D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997;112:1475-81.
73. Cuillerier E, Lemann M, Bouhnik Y, et al. Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study. Eur J Gastroenterol Hepatol 2001;13:1291-6.
74. Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004;127:730-7.
75. Keighley MR, Allan RN. Current status and influence of operation on perianal Crohn's disease. Int J Colorectal Dis 1986;1:104-7.
76. Hellers G, Bergstrand O, Ewerth S, et al. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut 1980;21:525-7.
77. Schwartz DA, Loftus EV, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875-80.
78. Haggett PJ, Moore NR, Shearman JD, et al. Pelvic and perineal complications of Crohn's disease: assessment using magnetic resonance imaging. Gut 1995;36:407-10.
79. Skalej M, Makowiec F, Weinlich M, et al. Magnetic resonance imaging in perianal Crohn's disease. Dtsch Med Wochenschr 1993;118:1791-6.
80. Koelbel G, Schmiedl U, Majer MC, et al. Diagnosis of fistulae and sinus tracts in patients with Crohn disease: value of MR imaging. Am J Roentgenol 1989;152:999-1003.
81. van Bodegraven AA, Sloots CE, Felt-Bersma RJ, et al. Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002;45:39-46.
82. Sloots CE, Felt-Bersma RJ, Poen AC, et al. Assessment and classification of fistula-in-ano in patients with Crohn's disease by hydrogen peroxide enhanced transanal ultrasound. Int J Colorectal Dis 2001;16:292-7.
83. Orsoni P, Barthet M, Portie F, et al. Prospective comparison of endosonography, magnetic resonance imaging and surgical findings in anorectal fistula and abscess complicating Crohn's disease. Br J Surg 1999;86:360-4.
84. Parks AG, Gordon PH, Hardcastle J. A classification of fistula-in-ano. Br J Surg 1976;63:1-12.
85. Bell SJ, Williams AB, Wiesel P, et al. The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther 2003;17:1145-51.
86. Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn's disease. Gastroenterology 2003;125:1508-30.
87. Berstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980;79:357-65.
88. Brandt LJ, Berstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982;83:383-7.
89. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984;79:533-40.
90. Solomon MJ, McLeod RS, O'Connor BI, et al. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. Can J Gastroenterol 1993;7:571-3.
91. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995;122:132-42.
92. Korelitz BI, Adler DJ, Mendelsohn RA, et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 1993;88:1198-205.
93. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
94. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
95. Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004;2:912-20.
96. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-9.
97. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000;95:3490-7.
98. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722-9.
99. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflam Bowel Dis 1995;1:48-63.
100. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 1997;92:876-9.
101. Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998;93:1860-6.
102. Lowry PW, Weaver AL, Tremaine WJ, et al. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis 1999;5:239-45.
103. Ierardi E, Principi M, Rendina M, et al. Oral tacrolimus (FK 506) in Crohn's disease complicated by fistulae of the perineum. J Clin Gastroenterol 2000;30:200-2.
104. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003;125:380-8.
105. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
106. Askling J, Grahnquist L, Ekbom A, et al. Incidence of paediatric Crohn's disease in Stockholm, Sweden. Lancet 1999;354:1179.
107. Armitage E, Drummond HE, Wilson DC, et al. Increasing incidence of both juvenile-onset Crohn's disease and ulcerative colitis in Scotland. Eur J Gastroenterol Hepatol 2001;13:1439-47.
108. Urne FU, Paerregaard A. [Chronic inflammatory bowel disease in children. An epidemiological study from eastern Denmark 1998-2000]. Ugeskr Laeger 2002;164:5810-14.
109. Hildebrand H, Finkel Y, Grahnquist L, et al. Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001. Gut 2003;52:1432-4.
110. Phavichitr N, Cameron DJ, Catto-Smith AG. Increasing incidence of Crohn's disease in Victorian children. J Gastroenterol Hepatol 2003;18:329-32.
111. Kolek A, Janout V, Tichy M, et al. The incidence of inflammatory bowel disease is increasing among children 15 years old and younger in the Czech Republic. J Pediatr Gastroenterol Nutr 2004;38:362-3.
112. Motil KJ, Grand RJ, Davis-Kraft L, et al. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993;105:681-91.
113. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003;88:995-1000.
114. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.
115. Weinstein TA, Levine M, Pettei MJ, et al. Age and family history at presentation of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2003;37:609-13.
116. Sun L, Roesler J, Rosen-Wolff A, et al. CARD15 genotype and phenotype analysis in 55 pediatric patients with Crohn disease from Saxony, Germany. J Pediatr Gastroenterol Nutr 2003;37:492-7.
117. Escher JC, Amil Dias J, Bochenek K, et al. Inflammatory Bowel Disease in children and adolescents. Recommendations for Diagnosis: The Porto criteria. Medical Position Paper: IBD working group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) J Pediatr Gastroenterol Nutr 2005;41:1-7.
118. Chong SK, Blackshaw AJ, Boyle S, et al. Histological diagnosis of chronic inflammatory bowel disease in childhood. Gut 1985;26:55-9.
119. Holmquist L, Rudic N, Ahren C, et al. The diagnostic value of colonoscopy compared with rectosigmoidoscopy in children and adolescents with symptoms of chronic inflammatory bowel disease of the colon. Scand J Gastroenterol 1988;23:577-84.
120. Cameron DJ. Upper and lower gastrointestinal endoscopy in children and adolescents with Crohn's disease: a prospective study. J Gastroenterol Hepatol 1991;6:355-8.
121. Williams CB, Nicholls S. Endoscopic features of chronic inflammatory bowel disease in childhood. Baillieres Clin Gastroenterol 1994;8:121-31.
122. Griffiths AMB. H.A. Inflammatory bowel disease. In: Walker WAD PR, Hamilton JR, et al. Pediatric gastrointestinal disease. Pathophysiology, diagnosis, management. Hamilton: BC Decker, 2000:613-51.
123. Esther JC, Ten KF, Lichtenbelt K, et al. Value of rectosigmoidoscopy with biopsies for diagnosis of inflammatory bowel disease in children. Inflamm Bowel Dis 2002;8:16-22.
124. Batres LA, Maller ES, Ruchelli E, et al. Terminal ileum intubation in pediatric colonoscopy and diagnostic value of conventional small bowel contrast radiography in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002;35:320-3.
125. Mashako MN, Cezard JP, Navarro J, et al. Crohn's disease lesions in the upper gastrointestinal tract: correlation between clinical, radiological, endoscopic, and histological features in adolescents and children. J Pediatr Gastroenterol Nutr 1989;8:442-6.
126. Abdullah BA, Gupta SK, Croffie JM, et al. The role of esophagogastroduodenoscopy in the initial evaluation of childhood inflammatory bowel disease: a 7-year study. J Pediatr Gastroenterol Nutr 2002;35:636-40.
127. Sharif F, McDermott M, Dillon M, et al. Focally enhanced gastritis in children with Crohn's disease and ulcerative colitis. Am J Gastroenterol 2002;97:1415-20.
128. Castellaneta SP, Afzal NA, Greenberg M, et al. Diagnostic role of upper gastrointestinal endoscopy in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004;39:257-61.
129. Lipson A, Bartram CI, Williams CB, et al. Barium studies and ileoscopy compared in children with suspected Crohn's disease. Clin Radiol 1990;41:5-8.
130. Halligan S, Nicholls S, Beattie RM, et al. The role of small bowel radiology in the diagnosis and management of Crohn's disease. Acta Paediatr 1995;84:1375-8.
131. Dillon M, Brown S, Casey W, et al. Colonoscopy under general anesthesia in children. Pediatrics 1998;102:381-3.
132. Wengrower D, Gozal D, Gozal Y, et al. Complicated endoscopic pediatric procedures using deep sedation and general anesthesia are safe in the endoscopy suite. Scand J Gastroenterol 2004;39:283-6.
133. Heuschkel RB, Menache CC, Megerian JT, et al. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000;31:8-15.
134. Levine A, Weizman Z, Broide E, et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003;36:248-52.
135. Escher JC. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004;16:47-54.
136. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
137. Mack DR, Young R, Kaufman SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998;132:830-5.
138. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000;137:192-6.
139. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-94.
140. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003;18:425-31.
141. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001;35:823-8.
142. Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003;98:104-11.
143. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2003;36:632-6.
144. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003;17:75-84.
145. de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in the Netherlands. J Pediatr Gastroenterol Nutr 2004;39:46-52.
146. Diamanti A, Papadatou B, Knafelz D, et al. Clinical outcome and safety of periodic infliximab therapy in children and adolescents with Crohn's disease. J Pediatr Gastroenterol Nutr 2004;39:302-3.
147. Lee WS. The use of infliximab in South-East Asian children with severe Crohn's disease. Pediatr Int 2004;46:198-201.
148. Miele E, Markowitz JE, Mamula P, et al. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004;38:502-8.
149. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004;36:342-7.
150. Lipson AB, Savage MO, Davies PS, et al. Acceleration of linear growth following intestinal resection for Crohn disease. Eur J Pediatr 1990;149:687-90.
151. Griffiths AM, Wesson DE, Shandling B, et al. Factors influencing postoperative recurrence of Crohn's disease in childhood. Gut 1991;32:491-5.
152. Besnard M, Jaby O, Mougenot JF, et al. Postoperative outcome of Crohn's disease in 30 children. Gut 1998;43:634-8.
153. Sentongo TA, Stettler N, Christian A, et al. Growth after intestinal resection for Crohn's disease in children, adolescents, and young adults. Inflamm Bowel Dis 2000;6:265-9.
154. Dokucu AI, Sarnacki S, Michel JL, et al. Indications and results of surgery in patients with Crohn's disease with onset under 10 years of age: a series of 18 patients. Eur J Pediatr Surg 2002;12:180-5.
155. Engstrom I, Lindquist BL. Inflammatory bowel disease in children and adolescents: a somatic and psychiatric investigation. Acta Paediatr Scand 1991;80:640-7.
156. van der Zaag-Loonen HJ, Grootenhuis MA, Last BF, et al. Coping strategies and quality of life of adolescents with inflammatory bowel disease. Qual Life Res 2004;13:1011-19.
157. Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology 1990;99:987-94.
158. Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut 1984;25:52-6.
159. Woolfson K, Cohen Z, McLeod RS. Crohn's disease and pregnancy. Dis Colon Rectum 1990;33:869-73.
160. Fonager K, Sorensen HT, Olsen J, et al. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol 1998;93:2426-30.
161. Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol 1984;6:211-16.
162. Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with Crohn's disease: a case control study by European collaborative group. Gut 1986;27:821-5.
163. Hudson M, Flett G, Sinclair TS, et al. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet 1997;58:229-37.
164. Ording OK, Juul S, Berndhson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002;122:15-19.
165. Olsen KO, Joelsson M, Laurberg S, et al. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg 1999;86:493-5.
166. Oresland T, Palmblad S, Ellstrom M, et al. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int J Colorectal Dis 1994;9:77-81.
167. Ravid A, Richard CS, Spencer LM, et al. Pregnancy, delivery, and pouch function after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2002;45:1283-8.
168. Tiainen J, Matikainen M, Hiltunen KM. Ileal J-pouch-anal anastomosis, sexual dysfunction, and fertility. Scand J Gastroenterol 1999;34:185-8.
169. Juhasz ES, Fozard B, Dozois RR, et al. Ileal pouch-anal anastomosis function following childbirth. An extended evaluation. Dis Colon Rectum 1995;38:159-65.
170. Damgaard B, Wettergren A, Kirkegaard P. Social and sexual function following ileal pouch-anal anastomosis. Dis Colon Rectum 1995;38:286-9.
171. Johnson E, Carlsen E, Nazir M, et al. Morbidity and functional outcome after restorative proctocolectomy for ulcerative colitis. Eur J Surg 2001;167:40-5.
172. Levi AJ, Fisher AM, Hughes L, et al. Male infertility due to sulphasalazine. Lancet 1979;2:276-8.
173. Birnie GG, McLeod TI, Watkinson G. Incidence of sulphasalazine-induced male infertility. Gut 1981;22:452-5.
174. O'Morain C, Smethurst P, Dore CJ, et al. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 1984;25:1078-84.
175. Toth A. Reversible toxic effect of salicylazosulfapyridine on semen quality. Fertil Steril 1979;31:538-40.
176. Dejaco C, Mittermaier C, Reinisch W, et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology 2001;121:1048-53.
177. Narendranathan M, Sandler RS, Suchindran CM, et al. Male infertility in inflammatory bowel disease. J Clin Gastroenterol 1989;11:403-6.
178. Hanan IM, Kirsner JB. Inflammatory bowel disease in the pregnant woman. Clin Perinatol 1985;12:669-82.
179. Larzilliere I, Beau P. [Chronic inflammatory bowel disease and pregnancy. Case control study]. Gastroenterol Clin Biol 1998;22:1056-60.
180. Miller JP. Inflammatory bowel disease in pregnancy: a review. J R Soc Med 1986;79:221-5.
181. Korelitz BI. Inflammatory bowel disease and pregnancy. Gastroenterol Clin North Am 1998;27:213-24.
182. Fedorkow DM, Persaud D, Nimrod CA. Inflammatory bowel disease: a controlled study of late pregnancy outcome. Am J Obstet Gynecol 1989;160:998-1001.
183. Mogadam M, Dobbins WO III, Korelitz BI, et al. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981;80:72-6.
184. Alstead EM. Inflammatory bowel disease in pregnancy. Postgrad Med J 2002;78:23-6.
185. Castiglione F, Pignata S, Morace F, et al. Effect of pregnancy on the clinical course of a cohort of women with inflammatory bowel disease. Ital J Gastroenterol 1996;28:199-204.
186. Nwokolo CU, Tan WC, Andrews HA, et al. Surgical resections in parous patients with distal ileal and colonic Crohn's disease. Gut 1994;35:220-3.
187. Buyon JP. The effects of pregnancy on autoimmune diseases. J Leukoc Biol 1998;63:281-7.
188. Ilnyckyji A, Blanchard JF, Rawsthorne P, et al. Perianal Crohn's disease and pregnancy: role of the mode of delivery. Am J Gastroenterol 1999;94:3274-8.
189. Nelson H, Dozois RR, Kelly KA, et al. The effect of pregnancy and delivery on the ileal pouch-anal anastomosis functions. Dis Colon Rectum 1989;32:384-8.
190. Ramalingam T, Box B, Mortensen NM. Pregnancy delivery and pouch function after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2003;46:1292.
191. Scott HJ, McLeod RS, Blair J, et al. Ileal pouch-anal anastomosis: pregnancy, delivery and pouch function. Int J Colorectal Dis 1996;11:84-7.
192. Nicholl MC, Thompson JM, Cocks PS. Stomas and pregnancy. Aust N Z J Obstet Gynaecol 1993;33:322-4.
193. Brandt LJ, Estabrook SG, Reinus JF. Results of a survey to evaluate whether vaginal delivery and episiotomy lead to perineal involvement in women
194. Subhani JM, Hamiliton MI. Review article: The management of inflammatory bowel disease during pregnancy. Aliment Pharmacol Ther 1998;12:1039-53.
195. Nielsen OH, Andreasson B, Bondesen S, et al. Pregnancy in Crohn's disease. Scand J Gastroenterol 1984;19:724-32.
196. Hill J, Clark A, Scott MA. Surgical treatment of acute manifestations of Crohn's disease during pregnancy. J R Soc Med 1997;90:64-6.
197. Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol Clin North Am 2003;32:323-40.
198. Jarnerot G, Into-Malmberg MB. Sulphasalazine treatment during breast feeding. Scand J Gastroenterol 1979;14:869-71.
199. Khan AK, Truelove SC. Placental and mammary transfer of sulphasalazine. BMJ 1979;ii:1553.
200. Esbjorner E, Jarnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand 1987;76:137-42.
201. Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998;114:23-8.
202. Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safely and clinical course. Gastroenterology 1993;105:1057-60.
203. Marteau P, Devaux CB. Mesalazine during pregnancy. Lancet 1994;344:1708-9.
204. Trallori G, d'Albasio G, Bardazzi G, et al. 5-Aminosalicylic acid in pregnancy: clinical report. Ital J Gastroenterol 1994;26:75-8.
205. Norgard B, Fonager K, Pedersen L, et al. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut 2003;52:243-7.
206. Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000;6:48-57.
207. Burtin P, Taddio A, Aribumu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995;172:525-9.
208. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998;42:1336-9.
209. Schaefer C, moura-Elefant E, Vial T, et al. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol 1996;69:83-9.
210. Brumfitt W, Pursell R. Trimethoprim-sulfamethoxazole in the treatment of bacteriuria in women. J Infect Dis 1973;128(suppl 65).
211. Decosta EJ, Belman MA. Cortisone and pregnancy; an experimental and clinical study of the effects of cortisone on gestation. Am J Obstet Gynecol 1952;64:746-67.
212. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998;338:1128-37.
213. Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet 2004;270:79-85.
214. Norjavaara E, de Verdier MG. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol 2003;111:736-42.
215. Kallen B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 1999;93:392-5.
216. Kihlstrom I, Lundberg C. Teratogenicity study of the new glucocorticosteroid budesonide in rabbits. Arzneimittelforschung 1987;37:43-6.
217. Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum 1995;38:1722-32.
218. Roubenoff R, Hoyt J, Petri M, et al. Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum 1988;18:88-110.
219. Willis FR, Findlay CA, Gorrie MJ, et al. Children of renal transplant recipient mothers. J Paediatr Child Health 2000;36:230-5.
220. Blatt J, Mulvihill JJ, Ziegler JL, et al. Pregnancy outcome following cancer chemotherapy. Am J Med 1980;69:828-32.
221. Nicholson HO. Cytotoxic drugs in pregnancy. Review of reported cases. J Obstet Gynaecol Br Commonw 1968;75:307-12.
222. Platzek T, Bochert G. Dose-response relationship of teratogenicity and prenatal-toxic risk estimation of 6-mercaptopurine riboside in mice. Teratog Carcinog Mutagen 1996;16:169-81.
223. Mosesso P, Palitti F. The genetic toxicology of 6-mercaptopurine. Mutat Res 1993;296:279-94.
224. Alstead EM, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990;99:443-6.
225. Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003;124:9-17.
226. Dejaco C, Angelberger S, Waldhoer T, et al. Pregnancy and birth outcome under thiopurine therapy for inflammatory bowel disease. Gastroenterology 2005;128(suppl 2):A12.
227. Rajapakse RO, Korelitz BI, Zlatanic J, et al. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol 2000;95:684-8.
228. Bar OB, Hackman R, Einarson T, et al. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001;71:1051-5.
229. Armenti VT, Ahlswede KM, Ahlswede BA, et al. National transplantation Pregnancy Registry-outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 1994;57:502-6.
230. Radomski JS, Ahlswede BA, Jarrell BE, et al. Outcomes of 500 pregnancies in 335 female kidney, liver, and heart transplant recipients. Transplant Proc 1995;27:1089-90.
231. Bertschinger P, Himmelmann A, Risti B, et al. Cyclosporine treatment of severe ulcerative colitis during 1 pregnancy. Am J Gastroenterol 1995;90:330.
232. Kainz A, Harabacz I, Cowlrick IS, et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 2000;70:1718-21.
233. Kozlowski RD, Steinbrunner JV, MacKenzie AH, et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990;88:589-92.
234. Kane S. Managing pregnancy in IBD. Inflammatory Bowel Disease Monitor 2002;4:2-11.
235. Vasiliauskas E, Dubinsky M, Barry M, et al. High serum levels of infliximab in the newborn of a mother receiving infliximab during pregnancy. Gastroenterology 2005;128(suppl 2):A26.
236. Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000;108:487-95.
237. Smithells RW, Newman CG. Recognition of thalidomide defects. J Med Genet 1992;29:716-23.
238. Pinder RM, Brogden RN, Sawyer PR, et al. Metoclopramide: a review of its pharmacological properties and clinical use. Drugs 1976;12:81-131.
239. Sahakian V, Rouse D, Sipes S, et al. Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: a randomized, double-blind placebo-controlled study. Obstet Gynecol 1991;78:33-6.
240. Siu SS, Yip SK, Cheung CW, et al. Treatment of intractable hyperemesis gravidarum by ondansetron. Eur J Obstet Gynecol Reprod Biol 2002;105:73-4.
241. Larson JD, Patatanian E, Miner PB, et al. Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy. Obstet Gynecol 1997;90:83-7.
242. Nikfar S, Abdollahi M, Moretti ME, et al. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci 2002;47:1526-9.
243. Stuart MJ, Gross SJ, Elrad H, et al. Effects of acetylsalicylic-acid ingestion on maternal and neonatal hemostasis. N Engl J Med 1982;307:909-12.
244. Kane S, Hanauer S. Fertility and pregnancy. In: Balfour Sartor R, Sandborn WJ, eds. Kirsner's inflammatory bowel disease. Philadelphia: Saunders, 2004:333-9.
245. Baron TH, Ramirez B, Richter JE. Gastrointestinal motility disorders during pregnancy. Ann Intern Med 1993;118:366-75.
246. Marteau P, Tennenbaum R, Elefant E, et al. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther 1998;12:1101-8.
247. Beitins IZ, Bayard F, Ances IG, et al. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 1972;81:936-45.
248. Ost L, Wettrell G, Bjorkhem I, et al. Prednisolone excretion in human milk. J Pediatr 1985;106:1008-11.
249. Christensen LA, Dahlerup JF, Schmiegelow K. Excretion of azathioprine metabolites in maternal milk. Gut 2005;54(suppl VII):A45.
250. Drossman DA. Presidential Address: Gastrointestinal illness and biopsychosocial model. Psychosom Med 1998;60:258-67.
251. Rubin GP, Hungin AP, Chinn DJ, et al. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther 2004;19:529-35.
252. Guthrie E, Jackson J, Shaffer J, et al. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. Am J Gastroenterol 2002;97:1994-9.
253. Nordin K, Pahlman L, Larsson K, et al. Health-related quality of life and psychological distress in a population-based sample of Swedish patients with inflammatory bowel disease. Scand J Gastroenterol 2002;37:450-7.
254. Kurina LM, Goldacre MJ, Yeates D, et al. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health 2001;55:716-20.
255. Drossman DA, Leserman J, Mitchell CM, et al. Health status and health care use in persons with inflammatory bowel disease. A national sample. Dig Dis Sci 1991;36:1746-55.
256. Helzer JE, Chammas S, Norland CC, et al. A study of the association between Crohn's disease and psychiatric illness. Gastroenterology 1984;86:324-30.
257. Casellas F, Lopez-Vivancos J, Badia X, et al. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol 2001;13:567-72.
258. Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 2002;16:1603-9.
259. Guassora AD, Kruuse C, Thomsen OO, et al. Quality of life study in a regional group of patients with Crohn's disease. A structured interview study. Scand J Gastroenterol 2000;35:1068-74.
260. Addolorato G, Capristo E, Stefanini GF, et al. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol 1997;32:1013-21.
261. Porcelli P, Leoci C, Guerra V. A prospective study of the relationship between disease activity and psychologic distress levels in patients with inflammatory bowel disease. Scand J Gastroenterol 1996;31:792-6.
262. Li J, Norgard B, Precht DH, et al. Psychological stress and inflammatory bowel disease: a follow-up study in parents who lost a child in Denmark. Am J Gastroenterol 2004;99:1129-33.
263. Engström I, Lindquist BL. Inflammatory bowel disease in children and adolescents: a somatic and psychiatric investigation. Acta Paediatr Scand 1991;89:640-7.
264. Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with IBD: a prospective 18-month follow-up study. Psychosom Med 2004;66:79-84.
265. Mardini HE, Kip KE, Wilson JW. Crohn's disease: a two-year prospective study of the association between psychological distress and disease activity. Dig Dis Sci 2004;49:492-7.
266. Andrews H, Barczak P, Allan RN. Psychiatric illness in patients with inflammatory bowel disease. Gut 1987;28:1600-4.
267. Wietersheim J, Kohler T, Feiereis H. Relapse-precipitating life events and feelings in patients with inflammatory bowel disease. Psychother Psychosom 1992;58:103-12.
268. North CS, Alpers DH, Helzer JE, et al. Do life events or depression exacerbate inflammatory bowel disease? A prospective study. Ann Intern Medicine 1991;114:381-6.
269. Duffy LC, Zielezny MA, Marshall JR, et al. Relevance of major stress events as an indicator of disease activity prevalence in inflammatory bowel disease. Behav Med 1991;17:101-10.
270. Gomez-Gil E, Vidal A, Panes J, et al. Relationship between patient's subjective stress perception and the course of inflammatory bowel disease. Gastroenterol Hepatol 2003;26:411-16.
271. Robertson DA, Ray J, Diamond I, et al. Personality profile and affective state of patients with inflammatory bowel disease. Gut 1989;30:623-6.
272. Nigro G, Angelini G, Grosso SB, et al. Psychiatric predictors of noncompliance in inflammatory bowel disease. J Clin Gastroenterol 2001;32:66-8.
273. Sewitch MJ, Abrahamowicz M, Bitton A, et al. Psychosocial correlates of patient-physician discordance in inflammatory bowel disease. Am J Gastroenterol 2002;97:2174-83.
274. Wietersheim J, Jantschek G, Sommer W, et al. Education of patients with inflammatory bowel diseases. Wien Med Wochenschr 1999;149:352-4.
275. Moser G, Tillinger W, Sachs G, et al. Disease-related worries and concerns: a study on out-patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995;9:853-8.
276. Kennedy A, Nelson E, Reeves D, et al. A randomised controlled trial to assess the impact of a package comprising a patient-orientated, evidence-based self-help guidebook and patient-centred consultations on disease management and satisfaction in inflammatory bowel disease. Health Technol Assess 2003;7:iii1-113.
277. Kennedy AP, Nelson E, Reeves D, et al. A randomised controlled trial to assess me effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease. Gut 2004;53:1639-45.
278. Borgaonkar MR, Townson G, Donnelly M, et al. Providing disease-related information worsens health-related quality of life in inflammatory bowel disease. Inflamm Bowel Dis 2002;8:264-9.
279. Lange A, Haslbeck E, Andus T, et al. Patient education in inflammatory bowel disease. Z Gastroenterol 1996;34:411-15.
280. Larsson K, Sundberg Hjelm M, et al. A group-based patient education programme for high-anxiety patients with Crohn disease or ulcerative colitis. Scand J Gastroenterol 2003;38:763-9.
281. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003;98:1535-44.
282. Guyatt GH, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
283. Irvine EJ, Zhou Q, Thompson AK, and the CCRPT Investigators. The short inflammatory bowel disease questionnaire: A quality of life instrument for community physicians managing inflammatory bowel disease. Am J Gastroenterol 1996;91:1571-8.
284. Drossman DA, Leserman J, Li Z, et al. The rating form of IBD patient concerns: A new measure of health status. Psychosom Med 1991;53:701-12.
285. Miehsler W, Weichselberger M, Offerlbauer-Ernst A, et al. Assessing the demand for psychological care in chronic diseases: development and validation of a questionnaire based on the example of inflammatory bowel disease. Inflamm Bowel Dis 2004;10:637-45.
286. Moser G. Psychosomatics [Diagnostics and treatment of Crohn's disease-results of an evidence-based consensus conference of the German Society for Digestive and Metabolic Diseases]. Z Gastroenterol 2003;41:50-1.
287. Moser G, Jantschek G. Psychosomatic [Diagnosis and therapy of ulcerative colitis: Results of an evidence-based consensus conference by the German Society of Digestive and Metabolic Diseases and the Competence Network on Inflammatory Bowel Disease]. Z Gastroenterol 2004;42:1038-40.
288. Sewitch MJ, Abrahamowicz M, Bitton A, et al. Psychological distress, social support, and disease activity in patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:1470-9.
289. Mussell M, Bocker U, Nagel N, et al. Reducing psychological distress in patients with inflammatory bowel disease by cognitive-behavioural treatment: exploratory study of effectiveness. Scand J Gastroenterol 2003;38:755-62.
290. Schwarz SP, Blanchard EB. Evaluation of psychological treatment for inflammatory bowel disease. Behav Res Ther 1991;29:167-77.
291. Milne B, Joachim G, Niedhardt J. A stress management program for inflammatory bowel disease patients. J Advan Nurs 1986;11:561-7.
292. Jantschek G, Zeitz M, Pritsch M, et al. Effect of psychotherapy on the course of Crohn's disease. Results of the German prospective multicenter psychotherapy treatment study on Crohn's disease. German Study Group on Psychosocial Intervention in Crohn's Disease. Scand J Gastroenterol 1998;33:1289-96.
293. Keller W, Pritsch M, Von Wietersheim J, et al. The German Study Group on Psychosocial Intervention in Crohn's Disease. Effect of psychotherapy and relaxation on the psychosocial and somatic course of Crohn's disease: main results of the German prospective multicenter psychotherapy treatment study on Crohn's disease. J Psychosom Res 2004;56:687-96.
294. Garcia-Vega E, Fernandez-Rodriguez C. A stress management programme for Crohn's disease. Behav Res Ther 2004;42:367-83.
295. Maunder RG, Esplen MJ. Supportive-expressive group psychotherapy for persons with inflammatory bowel disease. Can J Psychiatry 2001;46:622-6.
296. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:307-27.
297. Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975;68:627-35.
298. Rankin GB, Watts HD, Melnyk CS. National cooperative Crohn's disease study: extraintestinal manifestations and perianal complications. Gastroenterology 1979;77:914-20.
299. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998;42:387-91.
300. Fomaciari G, Salvarani C, Beltrami M, et al. Musculoskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001;15:399-403.
301. Puhakka KB, Jurik AG, Schiottz-Chritensen B, et al. MRI abnormalities of sacroiliac joints in early spondylarthropathy: a 1-year follow-up study. Scand J Rheumatol 2004;33:332-8.
302. Braun J, Baraliakos X, Golder W, et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 2004;63:1046-55.
303. Bjarnason I, Helgason KO, Geirsson AJ, et al. Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology 2003;125:1598-605.
304. Steer S, Jones H, Hibbert J, et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J Rheumatol 2003;30:518-22.
305. Ferraz MB, Tugwell P, Goldsmith CH, et al. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990;17:1482-6.
306. Dougados M, Dijkmans B, Khan M, et al. Conventional treatment for ankylosing spondylitis. Ann Rheum Dis 2002;61:40-50.
307. Cipolla G, Crema F, Sacco S, et al. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res 2002;46:1-6.
308. Evans JM, McMahon AD, Murray FE, et al. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997;40:619-22.
309. McCartney SA, Mitchell JA, Fairclough PD, et al. Selective COX-2 inhibitors and human inflammatory bowel disease. Aliment Pharmacol Ther 1999;13:1115-17.
310. Von Bodegraven A, Pena A. Treatment of extraintestinal manifestation in inflammatory bowel disease. Curr Treat Options Gastroenterol 2003;6:201-12.
311. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
312. Van den Bosch F, Kruithof E, Baeten D, et al. Randomised double blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthr Rheum 2002;46:755-65.
313. Scott EM, Gaywood I, Scott BB. British Society of Gastroenterology: Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. Gut 2000;46(suppl 1):i1-8.
314. Loftus EV Jr, Achenbach SJ, Sandborn WJ, et al. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2003;1:465-73.
315. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-81.
316. Stevenson M, Lloyd Jones M, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1-160.
317. Diamond TH. Pharmacotherapy of osteoporosis in men. Expert Opin Pharmocother 2005;6:45-58.
318. Requena L, Requena C. Erythema nodosum. Dermatol Online J 2002;8:4-8.
319. Chow R K, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996;34:1047-60.
320. Matis WI, Ellis CN, Griffiths CE, et al. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992;128:1060-4.
321. Jolles S, Niclasse S, Benson E. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol 1999;140:564-65.
322. Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with Crohn's disease: effect of TNF alpha blockade with infliximab. Scand J Gastroenterol 2002;37:1108-10.
323. Brooklyn T, Dunnill GS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosusm: a randomised, double-blind placebo-controlled trial. Gut, 2005;Sep 27;epub ahead of print.
324. Mintz R, Feller ER, Bahr RL, et al. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004;10:135-9.
325. Vitellas KM, Enns RA, Keogan MT, et al. Comparison of MR cholangiopancreatographic techniques with contrast-enhanced cholangiography in the evaluation of sclerosing cholangitis. Am J Roentgenol 2002;178:327-34.
326. Talwalkar JA, Angulo P, Johnson CD, et al. Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004;40:39-45.
327. MacFaul GR, Chapman RW. Sclerosing cholangitis. Curr Opin Gastroenterol 2004;20:275-80.
328. Lindor KD, and The Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic acid Study Group. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997;336:691-5.
329. Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-7.
330. Sjoqvist U, Tribukait B, Ost A, et al. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res 2004;24:3121-7.
331. Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus, a treatment for primary sclerosing cholangitis: results of an open label preliminary trial. Am J Gastroenterol 1995;90:455-9.
332. Hilsden RJ, Verhoef MJ, Best A, et al. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am J Gastroenterol 2003;98:1563-8.
333. Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis 2005;11:287-95.
334. Burgmann T, Rawsthorne P, Bernstein CN. Predictors of alternative and complementary medicine use in inflammatory bowel disease: do measures of conventional health care utilization relate to use? Am J Gastroenterol 2004;99:889-93.
335. Dick A, Keady S, Mohamed F, et al. Use of unlicensed and off-label medications in paediatric gastroenterology with a review of the commonly used formularies in the UK. Aliment Pharmacol Ther 2003;17:571-5.
336. Gerhardt H, Seifert F, Buvari P, et al. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 2001;39:11-17.
337. Gupta I, Parihar A, Malhotra P, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997;2:37-43.
338. Langmead L, Feakins RM, Goldthorpe S, et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 2004;19:739-47.
339. Joos S, Brinkhaus B, Maluche C, et al. Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion 2004;69:131-9.
340. Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334:1557-60.